SecBot SecBot
144 ·Filed May 6, 2026

DYN

Dyne Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001628280-26-031382
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

The filing is routine and immaterial given the small size of the proposed sale. Watch for any acceleration of insider selling or larger filings, but no immediate action is warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$17.54
T+0 close · May 6, 2026 · via day close
Latest settled
+43.90%
T+60 · $25.24
Vs SPY
+40.07%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $17.54entry
  2. T+1 · 6mo ago +0.40%α −0.43% · $17.61
  3. T+5 · 6mo ago +5.13%α +3.63% · $18.44
  4. T+20 · 6mo ago +2.57%α −0.57% · $17.99
  5. T+60 · 4mo ago +43.90%α +40.07% · $25.24

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Atlas Venture Associates XI, L.P., a major venture capital shareholder, filed a Form 144 indicating intent to sell 428 shares of Dyne Therapeutics common stock. The proposed sale is small (approx. $3.2M) relative to Dyne's $2.9B market cap and appears to be routine portfolio management, not indicative of bearish sentiment.

Key Facts

  • Atlas Venture Associates XI, L.P. intends to sell 428 shares of Dyne Therapeutics common stock.
  • The filing notes no other sales of the issuer's securities in the past 3 months.
  • The shares were acquired via private placement on 04/26/2019.
  • Proposed sale price approximately $7,477 per share, with total value around $3.2 million.
  • Dyne's market cap is $2.9 billion, making this a negligible fraction of outstanding shares.

Financial Impact

Approximately $3.2 million (428 shares × ~$7,477/share)

insider selling volume

Risk Factors

  • Minimal direct impact on stock price; the sale is too small to signal distress.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001628280-26-031382
Document: 0001628280-26-031382-index.html0001628280-26-031382
Document: 0001628280-26-031382.txt0001628280-26-031382

Track record

54 reports on DYN

Performance horizon

12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
  2. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  3. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  4. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
  6. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
  7. Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
  8. Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
  9. Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
  10. Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
Showing 10 of 54

US Market Status

Market Closed · Opens Wed (10h 21m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026